Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Patterson-UTI
PTEN
$4.16B
| $28.2M | 0.04% |
1,395,238
+411,040
| +42% | +$8.95M |
|
652
Amdocs
DOX
$6.23B
| $28.2M | 0.04% |
436,800
-75,100
| -15% | -$4.74M |
|
653
Amkor Technology
AMKR
$14.3B
| $28.1M | 0.04% |
2,878,800
-946,300
| -25% | -$10.7M |
|
654
Wheaton Precious Metals
WPM
$59.9B
| $28.1M | 0.04% |
1,411,597
+1,094,400
| +345% | +$22.4M |
|
|
SCLN
655
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| $27.9M | 0.04% |
2,540,200
+456,100
| +22% | +$4.56M |
|
|
DNKN
656
DELISTED
Dunkin' Brands Group, Inc.
DNKN
| $27.9M | 0.04% |
506,600
-54,000
| -10% | -$3.02M |
|
657
Stepan Co
SCL
$1.48B
| $27.9M | 0.04% |
320,200
+9,900
| +3% | +$832K |
|
658
The Mosaic Company
MOS
$6.92B
| $27.9M | 0.04% |
+1,219,900
| New | +$29.9M |
|
659
Emergent Biosolutions
EBS
$230M
| $27.8M | 0.04% |
820,411
+117,700
| +17% | +$3.63M |
|
660
Spok Holdings
SPOK
$230M
| $27.8M | 0.04% |
1,570,800
+17,300
| +1% | +$310K |
|
|
VWR
661
DELISTED
VWR Corporation
VWR
| $27.6M | 0.04% |
836,700
+650,700
| +350% | +$20.4M |
|
662
Sabre
SABR
$892M
| $27.6M | 0.04% |
+1,268,400
| New | +$28.9M |
|
|
BRSS
663
DELISTED
Global Brass & Copper Hldgs, Inc
BRSS
| $27.6M | 0.04% |
903,729
+84,929
| +10% | +$2.72M |
|
|
RHT
664
DELISTED
Red Hat Inc
RHT
| $27.5M | 0.04% |
+287,265
| New | +$25.6M |
|
665
NVR
NVR
$17B
| $27.5M | 0.04% |
11,410
-18,520
| -62% | -$41.7M |
|
666
Provident Financial Services
PFS
$3.26B
| $27.4M | 0.04% |
1,080,500
+16,400
| +2% | +$407K |
|
667
Perrigo
PRGO
$1.78B
| $27.4M | 0.03% |
+362,508
| New | +$26M |
|
668
Martin Marietta Materials
MLM
$32.7B
| $27.3M | 0.03% |
122,794
+120,900
| +6,383% | +$27.4M |
|
669
Louisiana-Pacific
LPX
$5.18B
| $27.3M | 0.03% |
1,133,400
-113,696
| -9% | -$2.77M |
|
670
Prestige Consumer Healthcare
PBH
$2.43B
| $27.3M | 0.03% |
516,500
+30,500
| +6% | +$1.63M |
|
671
Service Corp International
SCI
$11.3B
| $27.3M | 0.03% |
815,100
-396,900
| -33% | -$12.6M |
|
672
Atlantic Union Bankshares
AUB
$6.09B
| $27.2M | 0.03% |
803,745
+110,040
| +16% | +$3.75M |
|
|
PRA
673
DELISTED
ProAssurance
PRA
| $27.2M | 0.03% |
448,038
+96,238
| +27% | +$5.78M |
|
|
GRUB
674
DELISTED
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
| $27.2M | 0.03% |
+312,350
| New | +$25.9M |
|
675
Graphic Packaging
GPK
$3.51B
| $27.2M | 0.03% |
1,976,218
+1,914,400
| +3,097% | +$25.7M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.